Aileron Therapeutics, Inc.
(NASDAQ : ALRN)

( )
ALRN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.14%171.450.7%$971.15m
ABBVAbbVie, Inc. -0.04%138.011.9%$827.81m
PFEPfizer Inc. 0.20%49.350.9%$826.43m
LLYEli Lilly & Co. 0.04%301.441.1%$746.49m
MRKMerck & Co., Inc. 0.12%87.300.7%$738.96m
BMYBristol-Myers Squibb Co. 0.21%72.271.0%$651.18m
SIGASIGA Technologies, Inc. 3.48%24.110.0%$427.21m
AZNAstraZeneca Plc -0.67%65.591.0%$378.93m
ALNYAlnylam Pharmaceuticals, Inc. 0.00%218.588.1%$241.27m
GSKGSK Plc 0.10%40.610.3%$218.07m
HZNPHorizon Therapeutics Plc 0.00%69.605.4%$197.79m
SGENSeagen Inc. 1.21%177.935.7%$191.02m
NVSNovartis AG 0.50%86.000.2%$174.26m
RGENRepligen Corp. 0.00%246.276.7%$155.75m
NVONovo Nordisk A/S -0.46%102.740.1%$152.22m

Company Profile

Aileron Therapeutics, Inc. operates as a clinical stage biopharmaceutical company engaged in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III and Loren David Walensky on August 6, 2001 and is headquartered in Watertown, MA.